Loading clinical trials...
Loading clinical trials...
A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)
Conditions
Interventions
Mitomycin C
Gemcitabine
Locations
3
United States
Spectrum Health Medical Group-Division of Urology-LHCP
Grand Rapids, Michigan, United States
Spectrum Health Medical Group-Division of Urology
Grand Rapids, Michigan, United States
Urologic Consultants P.C.
Grand Rapids, Michigan, United States
Start Date
April 19, 2016
Primary Completion Date
October 22, 2021
Completion Date
October 22, 2021
Last Updated
April 21, 2023
NCT07222488
NCT05614739
NCT06441110
NCT06403202
NCT03459846
NCT02489890
Lead Sponsor
Corewell Health West
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions